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Abstract
Background: Transcriptional control of embryonic stem (ES) cell pluripotency has been a subject of intense study.
Transcriptional regulators including Oct4 (Oct3/4 index), Sox2 and Nanog are fundamental for maintaining the
undifferentiated state. However, the ES cell transcriptome is not limited to their targets, and exhibits considerable
complexity when assayed with microarray, MPSS, cDNA/EST sequencing, and SAGE technologies. To identify novel genes
associated with pluripotency, we globally searched for ES transcripts not corresponding to known genes, validated their
sequences, determined their expression profiles, and employed RNAi to test their function.
Results: Gene Identification Signature (GIS) analysis, a SAGE derivative distinguished by paired 5' and 3' transcript end
tags, identified 153 candidate novel transcriptional units (TUs) distinct from known genes in a mouse E14 ES mRNA
library. We focused on 16 TUs free of artefacts and mapping discrepancies, five of which were validated by RTPCR
product sequencing. Two of the TUs were revealed by annotation to represent novel protein-coding genes: a PRYdomain cluster member and a KRAB-domain zinc finger. The other three TUs represented intergenic splicing events
involving adjacent, functionally unrelated protein-coding genes transcribed in the same orientation, with one event
potentially encoding a fusion protein containing domains from both component genes (Clk2 and Scamp3). Expression
profiling using embryonic samples and adult tissue panels confirmed that three of the TUs were unique to or most highly
expressed in ES cells. Expression levels of all five TUs dropped dramatically during three distinct chemically induced
differentiation treatments of ES cells in culture. However, siRNA knockdowns of the TUs did not alter mRNA levels of
pluripotency or differentiation markers, and did not affect cell morphology.
Conclusion: Transcriptome libraries retain considerable potential for novel gene discovery despite massive recent
cDNA and EST sequencing efforts; cDNA and EST evidence for these ES cell TUs had been limited or absent. RTPCR
and full-length sequencing remain essential in resolving the bottleneck between numerous candidate novel transcripts
inferred from high-throughput sequencing and the small fraction that can be validated. RNAi results indicate that, despite
their strong association with pluripotency, these five transcriptomic novelties may not be required for maintaining it.
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Background
Embryonic stem (ES) cells are self-renewable cells able to
differentiate into virtually any cell type, an ability called
pluripotency (reviewed in [1]). Besides obvious therapeutic potential, pluripotency provides an opportunity to
understand how differentiation works in early embryonic
development. Many groups aim to characterize the 'stemness' of ES cells in terms of gene regulation and to identify
genes responsible for maintaining pluripotency. Although
the identification of the Oct4 (Oct3/4 index), Sox2 and
Nanog regulatory network [2,3] is a significant advance,
an integrated understanding is still lacking.
Some key approaches to understanding the molecular
basis of pluripotency and early differentiation are the
analysis of transcription factor binding site mapping [3],
epigenetics studies (reviewed in [4]), as well as in-depth
assessments of transcripts expressed in ES cells. Transcriptome surveys of ES cells by SAGE [5], MPSS [6,7], gene
trapping [8] and EST sequencing [9,10] have been performed by several groups under the hypothesis that transcripts expressed specifically in ES cells are instrumental
for maintaining pluripotency. Another transcript profiling
method which has been used to interogate ES cell transcriptome and offers a marked improvement compared to
those techniques is Gene Identification Signature (GIS)
analysis [11].
GIS analysis is a SAGE modification which isolates tags of
18 base pairs (bp) from the 5'- and 3'-ends of a transcript
and concatenates them to form Paired-End diTag (PET)
structures. Whereas SAGE extracts a single tag per transcript, GIS analysis presents paired sequence from transcript start and end sites, marking the boundaries of
transcriptional units (TUs) on the genome.
GIS analysis of mouse E14 ES cells generated 116,252 PET
sequences. Among them were hundreds of novel, uncharacterized TUs readily apparent on comparison of PET
boundaries with known-gene boundaries mapped to the
genome. The novel TUs were separated into four categories: new transcriptional start and end sites of known
genes, intergenic splicing connecting two adjacent genes
as a single transcript, trans-splicing events, and totally
novel transcripts.
Identification of novel transcripts from SAGE tags not
matching known genes has been reported before [12,13],
and heretofore unrecognized novel ES cell transcriptome
components have been hypothesized to be involved in
orchestrating the pluripotent state [5,8,9,14]. In one
major recent study, ES-specific SAGE tags have been earmarked for 3' cDNA cloning and subsequent evaluation of
the novel transcripts as potential regulators of the stemness phenotype [15].
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We also hypothesized that some ES-derived novel TUs
were expressed preferentially in undifferentiated ES cells,
as they had not been identified previously with other transcriptome characterisation techniques, and hence that
they may potentially be involved in maintaining pluripotency. Another example of this approach is the identification of Zfp206 as a transcription factor that controls
pluripotency in ES cells [16]. Building up from large-scale
EST and MPSS data which had indicated that the previously uncharacterized Zfp206 gene was differentially
expressed between pluripotent and differentiated states,
Wang et al. (2007) [16] found that Zfp206 regulates
pluripotency and is actively involved in the Oct4 and
Nanog regulatory loop.
To similarly accomplish discovery of novel pluripotencyassociated transcripts, we focused on two groups of novel
TUs inferred from GIS PET data: the fully novel transcripts
and the intergenic splicing events. Since GIS analysis provided sequence from 5'- and 3'-ends of the transcripts, we
physically validated and sequenced these TUs to reveal
their intron-exon structures. We analysed their splice junctions, alternative isoforms, open reading frames (ORFs),
and homologies to predict protein-coding potential. In an
attempt to relate the TUs to ES-specific functions, we profiled their expression in tissue panels and differentiation
timecourses, showing that the TUs were either ES-specific
or downregulated upon differentiation. We outline five
novel TUs to be further investigated for direct functional
roles in ES cells.

Results
Initial computational analysis of novel transcriptional
units in mouse embryonic stem cells
The initial dataset of 153 candidate unconventional PETsupported TUs consisted of 143 novel TUs not corresponding to known genes and 10 representing potential
intergenic splicing. We eliminated TU candidates with
multiple or ambiguous mappings, as described in Materials and Methods. Additionally, one novel and one intergenically spliced TU on the mm3 assembly matched
known genes on mm6 and were not analysed further.
Table 1 summarizes filtering results for novel and intergenically spliced candidate TUs with E14 ES PET support.

16 TUs were chosen for experimental validation: 10 novel
TUs with no known-gene support and 6 intergenically
spliced TUs. Their corresponding PETs were visualized
against the mm6 assembly to gauge the extent of mRNA
and EST support (the number of individual publicly available GenBank mRNAs and ESTs, respectively, whose
exons match one or both halves of a PET-transcriptome
tag in the same transcription orientation as the tag itself)
for these TUs. Eight TUs were supported at least partially
by full-length cDNAs and/or ESTs, but the other eight
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Table 1: Annotation-based filtering of candidate novel and intergenically spliced PET-based TUs.

Selection process

Initial dataset

Genomic span >
200 kb

Halftag/s within
repeats

Mapping to
multiple loci

Unmappable to
the genome

Novel
Intergenic Splicing
Total

143
10
153

48
48

48
48

26
26

10
3
13

No longer novel Final PETs

1
1
2

10
6
16

The numbers refer to PET counts in each named category corresponding to annotation-based filtering described in the text. The 'Mapping to
multiple loci' and 'Unmappable to the genome' columns are the combined results of both In-Silico PCR and BLASTN.

lacked support in public transcriptome databases and
were therefore completely novel (see Additional file 1 for
the characterization of these 16 TUs).
Expression validation, sequence analysis, and genomic
properties of novel TUs in mouse embryonic stem cells
We assayed the 16 novel TUs in mouse ES cells by RTPCR.
We obtained PCR products for 14 of the TUs. They were
sequenced and BLAT-aligned to the genome.

Four TUs (TUs 3, 8, 12 and 15) yielded non-specific
RTPCR products which did not map to the expected locus
after sequencing. For all of those TUs, there had been no
cDNA or EST evidence of nearby transcription along the
genome. As a result, only the PET half-tag (5'tag and 3'tag
[11]) sequences themselves were available for primer
design. The short length and low complexity of these
sequences likely resulted in suboptimal primers which
amplified non-specific products.
Three other TUs (TUs 6, 9 and 10) gave specific products
of sizes consistent with lack of splicing; two of these were
also potentially problematic due to intronic same-strand
localization relative to known genes. These seven TUs
were therefore excluded. Of the other seven PCR-positive
TUs, five yielded full-length sequences and became the
focus of remaining analyses (see Additional file 2 for their
full-length sequences).
TU4 (PET 1339): a novel PRY and SPRY domain-containing stem cell
gene
Three isoforms of TU4 were recovered by full-length
sequencing of RTPCR products. They were 1554, 1521
and 1397 bp long, named A [GenBank: EU599038], B
[GenBank: EU599039] and C [GenBank: EU599040]
respectively (Figure 1A). The longest isoform A had nine
exons while isoforms B and C contained eight and seven,
respectively. All splice junctions were canonical (GT-AG).

No spliced ESTs were present at this locus. Of the nine
unspliced ESTs overlapping exonic sequences of TU4, one
(CF894064) was from mouse ES cells and two
(CA542682 and BM208108) were from trophoblast stem
cells, as was the single full-length cDNA at the locus

(BC050214). This cDNA- and EST-derived expression profile was consistent with expression of this TU in ES cells.
The three ESTs supporting the 3'-halftag of the original
PET 1339 overlapped the last exon of TU4, while the other
ESTs and the cDNA partially were internal to the TU. This
implies that the diversity of TU4 full-length isoforms may
be considerably greater than demonstrated here.
The longest isoform had an ORF of 424 amino acids (aa),
from nucleotide (nt) 149 to nt 1423. This ORF contained
the conserved domains PRY and SPRY, an evolutionary
innovation associated with immunity [17]. It had homology to a predicted mouse protein similar to tripartite
motif protein 39 and to a predicted rat protein similar to
FLJ25801, which also contains PRY and SPRY domains.
Interestingly, TU4 shares a bidirectional promoter with
BC050188, another uncharacterized protein-coding gene,
through the EST BY710062. This EST constituted an alternative 5' end of BC050188 and was also of ES-cell origin.
BC050188 itself was supported by many other ES-cell
mRNAs and ESTs, and contained a partial PRY domain,
though its ORF was only 79 aa long. However, its human
putative ortholog, FLJ36180, had a 468-aa ORF with
RING, PRY, and SPRY domains. The promoter sharing
potential may imply a coregulatory and conserved relationship between these two tandemly arranged PRYdomain genes with ES-specific expression.
TU7 (PET 7295): a putative novel ES-specific transcription factor
TU7 had two isoforms, A [GenBank: EU599041] and B
[GenBank: EU599042] (1492 and 1428 bp long), with
five and four exons respectively. The splice junctions were
canonical. Exonic same-strand overlap with known ESTs
(Figure 1B), was observed. The structurally closest EST was
CA532373, derived from a mouse ES cell line.

The longest ORF was 270 aa, coded by nt 107–919 of isoform B. The ORF contained partial KRAB and FOG zinc
finger domains, homologous to a predicted protein similar to gonadotropin-inducible ovarian transcription factor
1. This suggests that TU7 may encode an ES-specific transcription factor.
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Figure 1 structures of novel TUs
Genomic
Genomic structures of novel TUs. A. TU4. B. TU7. C. TU11. D. TU52. E. TU54. Initial paired-end ditag: dark blue. Exons
of validated full-length cDNA sequences: orange. Exons of previously known transcripts at each locus: teal (protein-coding
sequence: shaded). 3' terminal exon arrows: direction of transcription. Quantitative real-time PCR primer locations: red
arrows. All validated cDNA sequences can be found in Additional file 2.
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TU11 (PET 31704): Slc10a3-Ubl4 intergenic splicing
TU11 connected the genes Slc10a3 and Ubl4. Taken separately, these two adjacent genes had numerous mRNAs
and ESTs in the public databases, but no public transcripts
connect the genes by intergenic splicing. We identified
three isoforms of this TU from E14 ES cells, 1038, 1002
and 829 bp long, labeled A [GenBank: EU599043], B
[GenBank: EU599044], and C [GenBank: EU599045]
respectively (Figure 1C). All isoforms spliced the 5'UTR of
Slc10a3 gene to a novel splice acceptor in the intergenic
region and continued into the remaining sequence of the
downstream Ubl4 gene. The two longer isoforms consisted of seven exons while the shortest had six, skipping
one exon of Ubl4. All splice junctions, including the novel
splice acceptors, were canonical, suggesting that this TU
was biologically transcribed and not a result of cDNA
library chimerism.

Only the two longer isoforms are likely to encode a protein; the 98-aa longest ORF of isoform C lacks any significant homology to Slc10a3, Ubl4, or any other proteins.
The longer isoforms A and B both potentially encoded a
157-aa ORF. This ORF contained the conserved domain
GDX_N in the first 61 aa and was homologous to Ubl4.
BLASTP search of NCBI ORF Finder results did not detect
any potential for chimeric protein formation, indicating
that Slc10a3 contributed exclusively the 5'UTR to the
Slc10a3-Ubl4 TU while the entire coding potential was
contributed by Ubl4. Therefore, despite intergenic splicing, the transcript would not encode a novel protein. It is
possible that regulatory sequences of Slc10a3, such as
RNA-binding protein cognate sites in the 5'UTR, are functionally united with the Ubl4 ORF by this intergenic splicing and may result in Slc10a3 sequence-mediated effects
on Ubl4 mRNA or protein levels.
TU52 (PET 34418): Clk2-Scamp3 intergenic splicing
TU52 connected the genes Clk2 and Scamp3. Each of the
component genes had good mRNA and EST support individually but none of the public transcripts bridged the two
genes into a single TU. In addition to the 2687-nt isoform
of this TU [GenBank: EU599046] validated in [11] (Figure
2 of that publication), we identified two isoforms of 2599
and 1962 nt, labeled A [GenBank: EU599047] and B
[GenBank: EU599048], respectively (Figure 1D).

Isoform A was similar to the 2687-nt published transcript
[11] but skipped exon 4 of Clk2. It consisted of 19 exons,
with all splice junctions being GT-AG. Isoform B had 14
exons and, likewise, all splice junctions were canonical.
All three isoforms skipped the last exon of Clk2 and
spliced into different Scamp3 splice acceptors, presumably as a consequence of transcriptional read-through. Isoform A and the published transcript spliced into the
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second exon of Scamp3 while isoform B spliced into the
penultimate exon of Scamp3.
Isoform A had a 407-aa ORF (nt 703 to nt 1926) and, similarly to the published transcript, encoded a chimeric protein with components from both genes. The predicted
protein contained the STKc (Serine/Threonine protein
kinases, catalytic) domain from Clk2 and the SCAMP
domain from Scamp3.
Clk2 may be involved in regulation of alternative splicing
[18] and our result indicates that Clk2 itself may be alternatively spliced. Human SCAMP3 is known to undergo a
specific tyrosine phosphorylation event, leading potentially to downregulation of the human EGF receptor [19].
The presence of the Clk2 kinase domain in the fused transcript might imply auto-regulation of the Scamp3 fragment of the chimeric protein by self-phosphorylation, a
regulatory context distinct from conventional post-translational processing of Scamp3.
Isoform B had a longer ORF of 517 aa (nt 107 to nt 1660).
However, this 517-aa longest ORF of the Isoform B mRNA
only contained the STKc domain and was solely homologous to the Clk2 protein, because the Scamp3 protein
sequence in this isoform was encoded in a different reading frame. Therefore, despite intergenic splicing, isoform
B does not encode a chimeric protein.
TU54 (PET 48740): 1110034A24Rik-Rpl36al intergenic splicing
Intergenically spliced TU54 [GenBank: EU599049] connected the 1110034A24Rik and Rpl36al genes. The TU,
1147 bp long, has four exons with canonical splice junctions (Figure 1E). There were numerous cDNAs and ESTs
supporting each gene separately, but none bridged the
two. This TU overlapped in the reverse (cis-antisense) orientation the Mgat2 gene between 1110034A24Rik and
Rpl36al.

The longest ORF of this TU was 166 aa (nt 278 to 778). It
contained no conserved domains and was identical to the
standalone 1110034A24Rik ORF. After the stop codon at
nt 778 there was another 100-aa ORF identical to Rpl36al.
Therefore, this intergenically spliced TU was potentially
bicistronic, containing the complete ORFs of both component genes, but did not encode a fusion protein.
The cis-antisense overlap with Mgat2 was 58 nt, comprising the entire third exon of this TU which overlaps part of
the coding sequence of Mgat2. Expression of the
1110034A24Rik-Rpl36al bicistronic TU may exert regulatory effect on Mgat through the cis-antisense pairing, as
genes in other cis-antisense gene pairs can affect each
other's expression [20].
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We then investigated whether these new members of the
ES cell transcriptome are regulated by known ES transcription factors. To accomplish this, we searched two datasets
of experimentally supported transcription factor binding
events for Oct4, Nanog, and Sox2 binding sites in the
vicinity of the TUs: chromatin immunoprecipitation
paired-end diTags (ChIP-PET) [3] and ChIP-sequencing
by Solexa technology [H. H. Ng et al., unpublished]. In
brief, all TUs had evidence of Oct4, Nanog, and/or Sox2
binding events within 100 kb of the TU in one or both
types of ChIP datasets (See Additional file 3). Most notably, TU7 had Oct4 and Nanog binding sites 27.5 kb
downstream of its 3' end, while TU52 had a Sox2 binding
site 42.5 kb downstream of its 3' end supported by both
Sox2 ChIP datasets. Only one binding event – a ChIP-seq
Nanog binding site – was localized directly at the transcription start site, for TU4.
Qualitative and quantitative expression profiling of novel
TUs
Since the TUs were newly recognized components of the
mouse ES cell transcriptome, the fact that they had never
been detected before in any other cell type suggested that
they might be preferentially expressed in ES cells. We thus
hypothesized that they may be involved in the maintenance of pluripotency in these cells and accordingly,
checked their expression in stem cells and a panel of
embryonic and adult tissues, because higher expression in
undifferentiated cells would be consistent with a function
specific to such cells. An example of this pattern of gene
expression is LIN28 which was found by SAGE to be
expressed only in human ES cells [5] and showed downregulation upon ES cell differentiation. In fact, LIN28 has
only been recently implicated in human somatic cell
reprogramming back to the pluripotent state [21], indicating its importance in ES cells.

Conventional RTPCR and quantitative real-time PCR
(QRTPCR) were used to profile expression of the novel
TUs. The results, discussed further, showed that all five
TUs were either ES-specific or were expressed most highly
in ES cells despite being also transcribed elsewhere.
To further confirm the pluripotency association of the
TUs, we also measured the changes in expression levels of
the TUs in ES cells upon chemical induction of differentiation. ES cells were differentiated using retinoic acid (RA),
dimethyl sulfoxide (DMSO), and hexamethylene bisacetamide (HMBA) treatments, in separate experiments.
The three treatments served also to eliminate the possibility of chemical-specific expression responses.
To validate that the three chemical treatments reduced
pluripotency marker levels and led the cells to differentiate, we tested expression levels of four principal pluripo-
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tency markers (Oct4, Sox2, Nanog and Klf4) by TaqMan
QRTPCR. The results clearly indicated that all pluripotency marker mRNA levels decreased over time in all three
treatment timecourses, proving that the treatments led to
the expected differentiation outcomes (See Additional file
4).
QRTPCR was performed to determine the effect of differentiation on the RNA level of the novel TUs. We demonstrated that most of the TUs were consistently
downregulated upon differentiation, regardless of the differentiation agents used.
TU4 (PET 1339): a novel stem cell gene with PRY and SPRY domains
Qualitative RTPCR on the multitissue panel suggested
that TU4 had an ES-cell-specific expression pattern (Figure
2A and 2B). We did not detect expression of this TU outside of ES cells by RTPCR (data not shown). QRTPCR
demonstrated that expression of this TU was low though
not absent in non-ES samples. The second-highest expression level was in adult skeletal muscle, at 30% of the EScell level; in the few other tissues where the TU was
expressed, its RNA level was less than 20% of the ES-cell
level (Figure 2B). Consistent downregulation of this TU
upon ES cell differentiation was evident in all three differentiation timecourses, although it was most pronounced
with DMSO treatment (Figure 2C).
TU7 (PET 7295): a putative novel ES-specific transcription factor
This novel TU showed a similar expression pattern to TU4.
Qualitative RTPCR indicated that besides expression in ES
cells this TU had barely-detectable expression in the
embryo at days seven and eleven (Figure 3A). QRTPCR
confirmed the ES specificity of TU7 (Figure 3B).

The expression level of TU7, similarly to TU4, showed a
decreasing trend upon ES cell differentiation (Figure 3C).
This gradual effect was observed in all three treatments
but the decrease was not as rapid as that of TU4. A significant reduction in TU7 expression was observed after four
days of RA treatment whereas for TU4 the effect was
observed as early as day two. In the other differentiation
treatments, the effect was similar between the two genes,
with DMSO treatment yielding the strongest response.
This expression profile argues in favor of potential relevance of TU7 to ES cell pluripotency.
TU11 (PET 31704): Slc10a3-Ubl4 intergenic splicing
Qualitative RTPCR suggested that the intergenically
spliced Slc10a3-Ubl4 TU had a close-to-ubiquitous
expression profile (Figure 4A), although it nevertheless
was preferentially expressed in embryonic rather than
adult tissues. One adult sample with higher expression of
Slc10a3-Ubl4 than ES cells was testes (Figure 4B). This is
intriguing because adult testes reportedly contain
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Mkr, 1-kb ladder;
E14, mouse E14 ES cells.

A

mkr E14
B

Error bars (panels B and C): two technical replicates each of two biological replicates.
C

Figure 2 profile of TU4
Expression
Expression profile of TU4. A. Qualitative RTPCR (samples testing negative are not shown). B. Quantitative RTPCR: wholeembryo and tissue panel. C. Quantitative RTPCR: retinoic acid (RA), dimethyl sulfoxide (DO), and hexamethylene bisacetamide (HM)-induced differentiation time courses of E14 ES (left to right: untreated; days 2, 4, 6).
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Mkr, 1-kb ladder;
E14, mouse E14 ES cells;
Em7, whole embryo day 7;
Em11, whole embryo day 11.

A

mkr

E14 Em7 Em11

B

Error bars (panels B and C): two technical replicates each of two biological replicates.
C

Figure 3 profile of TU7
Expression
Expression profile of TU7. A. Qualitative RTPCR (samples testing negative are not shown). B. Quantitative RTPCR: wholeembryo and tissue panel. C. Quantitative RTPCR: retinoic acid (RA), dimethyl sulfoxide (DO), and hexamethylene bisacetamide (HM)-induced differentiation time courses of E14 ES (left to right: untreated; days 2, 4, 6).
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A
1 kb
1 2

B

3

4

5 6

7 8

9 10 11 12 13 14 15 16 17

A and B: 1, E14 ES cells; 2-5,
whole embryo (days 7, 11, 15, 17);
6, brain; 7, colon; 8, heart;
9, kidney; 10, liver; 11, lung;
12, ovary; 13, skeletal muscle;
14, spleen; 15, stomach;
16, testis; 17, thymus.

Error bars (panels B and C): two technical replicates each of two biological replicates.
C

Figure 4 profiles of TU11, an intergenically spliced product of the Slc10a3-Ubl4 locus, and its component genes
Expression
Expression profiles of TU11, an intergenically spliced product of the Slc10a3-Ubl4 locus, and its component
genes. A. Qualitative RTPCR. B. Quantitative RTPCR: whole-embryo and tissue panel. C. Quantitative RTPCR: retinoic acid
(RA), dimethyl sulfoxide (DO), and hexamethylene bisacetamide (HM)-induced differentiation time courses of E14 ES (left to
right: untreated; days 2, 4, 6).
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multipotent cells capable of forming derivatives of the
three embryonic layers [22].
QRTPCR showed that this bicistronic TU was downregulated upon differentiation (Figure 4C). DMSO and HMBA
differentiation timecourses resulted in a more rapid
downregulation of Slc10a3-Ubl4, giving it an expression
profile recapitulating that of TU7.
To verify that this intergenically spliced TU was involved
in pluripotency but its component genes were not, we
individually measured expression levels of the component genes, Slc10a3 and Ubl4. A correlation between the
expression level of the bicistronic TU and expression levels of its component genes would suggest that Slc10a3Ubl4 was not an independently regulated TU.
However, the expression level of this TU was markedly different from those of the component genes, both in the
multitissue panel and in all three differentiation timecourses (Figure 4B and 4C respectively). In the multitissue
panel Slc10a3 was highly upregulated in adult tissues,
especially in heart, kidney, and liver, while Ubl4 expression was high in the heart and skeletal muscle relative to
E14 ES cells. In the differentiation timecourses, the component genes did not show any down regulation effect
upon induction of differentiation. In fact, they were
upregulated, especially upon DMSO treatment. This result
showed that although this bicistronic TU contained the 5'
UTR of Slc10a3, its regulation did not simply reflect the
expression profile of that gene. We conclude that Slc10a3Ubl4 is a genuine novel transcript regulated independently of its component genes. Furthermore, we propose
that this locus may undergo expression regulation by a
combination of alternative splicing and preferential transcription initiation at the downstream Ubl4 promoter,
such that intergenic splicing is favored in ES cells while
independent transcription of the component genes occurs
preferentially in differentiated tissues.
TU52 (PET 34418): Clk2-Scamp3 intergenic splicing
Based on qualitative RTPCR, TU52 appeared largely ESspecific, with some embryonic expression (Figure 5A).
The only adult tissue samples that showed a visible band
were skeletal muscle and testes. QRTPCR showed that
expression level in testes was approximately fivefold
greater than the ES-cell level (Figure 5B).

Upon ES cell differentiation, the Clk2-Scamp3 TU showed
significant downregulation (Figure 5C). In RA- and
HMBA-treated cells the gene showed a similar expression
profile with a maximum decrease to 20% of the ES-cell
level after four days of treatment. In the DMSO timecourse this effect was less pronounced.
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TU54 (PET 48740): 1110034A24Rik-Rpl36al intergenic splicing
Qualitative RTPCR of the intergenically spliced
1110034A24Rik-Rpl36al TU showed that it was not ES
cell-specific, as multiple embryonic and adult samples
showed detectable expression (Figure 6A). However,
QRTPCR indicated that the highest expression level was
still in ES cells (Figure 6B).

Accordingly, RA, DMSO and HMBA treatments all
showed that expression of 1110034A24Rik-Rpl36al
decreased as the cells differentiated (Figure 6C). This
decrease was significant in all of the timecourses tested
with up to 80% reduction in mRNA expression in RAtreated cells at day six and up to 90% decrease in both
DMSO- and HMBA-treated cells.
RNAi-based functional analysis of novel TUs
We designed 4-siRNA combinations targeting TU4 and
TU7 and individual siRNAs uniquely targeting the intergenically spliced TU11, TU52, and TU54 transcripts (see
Methods for design notes). We were unable to achieve satisfactory TU54 knockdown (data not shown). We accomplished knockdowns of the other four TUs to 25% – 55%
of control (non-targeting siRNA transfection) mRNA levels (Figure 7).

We hypothesized that, if the novel TUs were relevant to
maintaining ES cell pluripotency instead of merely associated with pluripotency, then depletion of RNA levels of
the TUs could result in depletion of mRNA levels of some,
or all, of the four principal pluripotency-driving transcription factors (Oct4, Sox2, Klf4, and Nanog). Although both
Nanog and Klf4 expression levels were reduced to 70% of
reference upon knockdown of TU7, no downregulation of
the Oct4 or Sox2 was observed. There was no downregulation of Oct4, Sox2, Klf4, or Nanog upon knock down of
the other novel TUs (Figure 7).
We also reasoned that, if the TUs were indeed required for
maintaining the ES state, then RNAi suppression of the TU
RNA levels could lead to upregulation of well-known
ectodermal, endodermal, and mesodermal lineage markers. We therefore tested, by QRTPCR with commercially
available primer sets and fluorescent probes (TaqMan,
Applied Biosystems), the mRNA levels of ectodermal
(Fgf5, Nestin, Sox1, Sox4, Pax6, Pax7, Rest), endodermal
(Sox17, Gata4, Gata6, Foxa2, Afp), and mesodermal
(Gata2, Nkx2.5, T-brachyury, MyoD, Hand1, and Bmp4)
differentiation markers after independent TU4, TU7,
TU11, and TU52 RNAi transfections.
Differentiation marker levels were unaffected by TU4,
TU11, and TU52 RNAi. Upregulation of Fgf5 (but not any
other ectodermal markers) and T-brachyury (but not any
other mesodermal markers), to approximately 150% of
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Error bars (panels B and C): two technical replicates each of two biological replicates.
C

Figure 5 profile of TU52, an intergenically spliced product of the Clk2-Scamp3 locus
Expression
Expression profile of TU52, an intergenically spliced product of the Clk2-Scamp3 locus. A. Qualitative RTPCR. B.
Quantitative RTPCR: whole-embryo and tissue panel. C. Quantitative RTPCR: retinoic acid (RA), dimethyl sulfoxide (DO), and
hexamethylene bisacetamide (HM)-induced differentiation time courses of E14 ES (left to right: untreated; days 2, 4, 6).
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Figure 6 profile of TU54, an intergenically spliced product of the 1110034A24Rik-Rpl36al locus
Expression
Expression profile of TU54, an intergenically spliced product of the 1110034A24Rik-Rpl36al locus. A. Qualitative
RTPCR (samples testing negative: not shown). B. Quantitative RTPCR: whole-embryo and tissue panel. C. Quantitative
RTPCR: retinoic acid (RA), dimethyl sulfoxide (DO), and hexamethylene bisacetamide (HM)-induced differentiation time
courses of E14ES (left to right: untreated; days 2, 4, 6).
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Figure 7 levels of pluripotency markers upon siRNA knockdown of the novel TUs
Expression
Expression levels of pluripotency markers upon siRNA knockdown of the novel TUs. Nanog and Klf4 expression
was reduced to 70% upon knockdown of TU7 but no down regulation of the other pluripotency markers was observed. There
was no down regulation of Oct4, Sox2, Nanog and Klf4 upon knockdown of the other novel TUs. Expression level was measured relative to Non-Targeting siRNA control (100%). Error bars indicate S.E.M. from two biological replicates.
reference levels each, was observed at day 3 and day 5
post-TU7 RNAi (data not shown). Nanog, Klf4, Fgf5, and
T-brachyury were reproducibly affected by TU7 perturbation, making a direct function of TU7 in pluripotency
maintenance possible in principle. However, the lack of
generalized effects on pluripotency transcription factors
and differentiation marker classes suggests that even TU7
may not be an essential pluripotency regulator.

Discussion
Validation rate of novel TUs from a PET-transcriptome
library
The five novel TUs whose transcription and full-length
sequence we validated represent only a small subset
(3.3%) of candidate novel TUs revealed by PET-based

mES transcriptome sampling. We ascribe this small fraction to our selection criteria implemented in selecting TUs
to be validated. The criteria were designed to maximize
the chance of experimental validation but do not imply
that all remaining TUs are artefactual.
To sample a larger number of TUs for future physical validation, selection criteria can be relaxed. For example, the
200 kb cutoff value for maximum genomic span can be
increased since some genes are an order of magnitude
longer (for example, Dmd [23]). Two putative bicistronic
TUs which were excluded from the original dataset would
have been detected if the cutoff had been increased to 1
Mb.
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Among TUs selected for physical validation, only five
yielded specific products. One reason for the low efficiency is likely the limited PET sequence available for
primer selection, the crucial point of the validation process. It is possible that the primers designed from the PET
sequence were suboptimal and unable to bind to the correct transcript resulting in both false negative and false
positive PCR results. The presence of ESTs and flcDNAs in
the locus clearly aids validations as it increases the
amount of known exonic sequence space putatively
belonging to the PET-supported TU; utilizing this space
benefits primer design.
Ng et al. (2005) verified a large proportion of PET-supported mES transcripts (94.4%). However, they used their
own GIS flcDNA library as the template source. Thus,
some of their confirmed TUs were likely due either to
experimental artefacts or to extremely rare transcripts
which were clonally propagated in that library, but might
not be present at detectable levels in normal E14 cells. We
used RNA from E14 cells for our analysis. Furthermore,
the high success rate obtained by Ng et al. was for a combination of novel and known genes; the validation rate for
novel TUs alone was not explicitly specified. These factors
might account for our lower validation rate.
Intergenic Splicing
Three of our five novel TUs join two adjacent genes by
forming a single transcript containing exonic sequences of
both genes. Despite sporadic reports of intergenic splicing
(reviewed in [24,25]), its biological significance is largely
unknown. Several models speculate on how such transcriptional gene fusion may have a physiological role.
First, the fusion may be a byproduct of transcriptional
read-through, whereby the transcriptional machinery
does not stop at the transcription stop site of the first gene
but "reads-through" to the 3' end of the next gene on the
same strand instead. These can be rare unregulated stochastic events with no functional significance. However,
we showed that our transcripts were not present just in ES
cells; they were frequently detectable in several, though
not all, cell and tissue types, but never ubiquitous, and the
expression levels differed reproducibly between samples.
Consequently, the intergenic splicing events we observed
are unlikely to be random.

Second, chimeric TUs – those with fusion ORFs in addition to intergenic splicing – can form novel and truly functional proteins. The fusion can create a new bifunctional
protein, as is the case in the TWEAK-APRIL fusion [26], or
change the properties of one of the participating proteins.
An example of the latter case is the Kua-UBE2V1 fusion
[27] where the fused protein is cytoplasmic while the original UBE2V1 is nuclear. Only one of our three intergenically spliced TUs has a putatively chimeric fusion ORF,
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however. Only 25% of intergenically spliced genes
detected in a recent study encode chimeric proteins [24].
A less clear functional impact of intergenic splicing centers
on expression regulation. A theoretical example is the
bicistronic TU11 which contained the 5' UTR of the
upstream Slc10a3 gene and the entire coding sequence of
the downstream Ubl4 gene. Since TU11 contained the
5'UTR of Slc10a3 it could be hypothesized that the bicistronic transcript would be co-regulated together with the
upstream gene. However, analysis of their expression level
showed that TU11 was regulated independently from its
two component genes. There might be other consequences of the hybrid "5'UTR of gene 1 – ORF of gene 2"
composition of this TU, for example potential for regulation of Ubl4 by RNA-binding proteins which only recognize specific sites in the 5'UTR of Slc10a3.
Despite the scale of the intergenic splicing datasets
reported in [24] and [25], neither study identified intergenic splicing at the three loci corresponding to our TUs.
In fact, even a recent high-throughput effort to catalog
novel components of the mouse ES transcriptome [8] did
not yield any evidence of intergenic splicing at our three
loci, although gene trap tags corresponding individually
to Ubl4, Clk2, Scamp3, and Rpl36al were isolated in that
project. This shows that diversity and genomewide incidence of this phenomenon exceed current estimates, and
emphasizes the need for targeted validation of candidates
from specific libraries, such as our mES transcriptome
library, to gain insight into the diversity of intergenic
splicing in transcriptomes previously not subjected to
deep sampling.
Relevance to pluripotency of ES cells
In addition to reporting novel TUs in mouse ES cells, we
provide preliminary evidence for their functional significance. Since the novel TUs were initially found in undifferentiated ES cells, we hypothesized that they were
involved in ES cell pluripotency. Our findings initially
supported this hypothesis since almost all of the TUs we
reported here were preferentially expressed in ES cells
compared to adult tissues, and all TUs had nearby Oct4,
Sox2, and Nanog binding sites confirmed by two independent lines of ChIP evidence. This suggests an importance of these TUs in ES, rather than differentiated, cells,
although it does not preclude functional roles in other
contexts.

More direct support for our hypothesis is provided by the
downregulation of these TUs upon ES cell differentiation.
The effect was common to all three differentiation treatments tested, indicating that it was not a chemical-specific
response, but rather a reproducible outcome of differentiation. Combined with the EST-derived expression profiles
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and multi tissue expression analysis, this result further
implicates the five TUs in maintaining ES cell pluripotency.
Loss-of-function experiments for four of these novel TUs
did not lead to cell differentiation as can be seen from the
levels of pluripotency markers Oct4, Sox2, Nanog and
Klf4 upon siRNA transfections. However, TU7 was intriguing because its knockdown led to approximately 30%
concurrent reduction in Klf4 and Nanog levels, as well as
to 1.5-fold upregulation of Fgf5 and T-brachyury. It has
been known that T-brachyury is able to upregulate Nanog,
which in turn suppresses T-brachyury's own expression in
an indirect, Smad-facilitated negative feedback loop in
early mesodermal progenitors [28,29]. If an identical Tbrachyury/Nanog relationship exists in undifferentiated
ES cells or in an early mesodermal progenitor subpopulation thereof, then it is possible that TU7 may be a contributor in maintaining Nanog levels in undifferentiated ES
cells so that when its expression is knocked down Nanog
level is no longer maintained and the suppression of Tbrachyury is lost.
Summarily however, these five TUs alone, without
unknown cofactors, are not necessary or sufficient for
maintaining pluripotency. Overexpression of the TUs, in
transient or stable transfectants, could be attempted as an
additional functional test in order to determine whether
higher levels of the TU RNAs enable ES cells to resist
chemical differentiation drivers. While an in-silico or
computational subtractive-hybridization comparison
with a non-ES transcriptome would be appropriate, there
was no non-ES PET transcriptome dataset generated by Ng
et al. [11], precluding direct quantitative comparison of
these novel TUs' expression in ES vs. non-ES states.

Conclusion
Our observations summarily demonstrate that all five TUs
we analyzed represent genuine novel transcripts potentially important in maintaining pluripotency. To elucidate
the biological importance of these novel TUs, RNAi
knock-downs were performed, which indicated that RNA
level ablation of TU7 leads to a modicum of reproducible
expression profile changes associated with the three principal cell differentiation fates while such ablation of the
other four TUs failed to change expression phenotypes.
Nevertheless, our results establish a foundation for functional analysis of a small number of novel TUs filtered
from a large set of candidates, and show that the GIS mES
PET-transcriptome library is a good resource for identification of novel TUs highly expressed in, and specific to, ES
cells.
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Methods
GIS dataset
TUs not corresponding to known genes were obtained by
screening the transcriptome data from [11] for PET clusters which were > 10 kilobases (kb) away from known
genes at one or both ends. TUs with putative intergenic
splicing were obtained from Supplementary Table 3 of
that publication. PET index numbers, paired halftag
sequences, and PET alignments to the mm3 genome
assembly were retrieved from the sme003_63467Apr22b
dataset at the T2G public website [30] (See Additional file
1 for the detailed PET sequences used in this analysis).
Computational analysis
Genomic alignments and repeat content of PET sequences
BLAT [31,32] was used to align PET sequences and the
full-length TU sequences we obtained to the mouse mm6
genome assembly, the latest available as of the inception
of the project. The RepeatMasker track of the UCSC
Browser was used to determine whether each PET halftag
localized to repetitive sequence. 48 PETs were removed
because they overlapped repetitive elements.

The halftag sequences of each PET were used as UCSC insilico PCR [33] primers on the mm6 assembly. Default
parameters were used, with a 200-kb maximum product
size to reduce potential artifacts; 10 PETs were removed
due to this threshold. Three PETs that were shown to
ambiguously map to multiple genomic loci and six PETs
that did not return any result, indicating that their halftags
were not present in tandem on the mm6 genome assembly, were subsequently eliminated.
Specificity check of non-repetitive PETs with unique mappings
NCBI BLASTN with the "Search for short, nearly exact
matches" option [34] was run separately for each halftag
of each PET, using default parameters and limited to the
Mus musculus subbase of the NR database. The goal of this
analysis was to eliminate halftag sequences which, despite
unique in-silico PCR mappings, could compromise
RTPCR primer design. This eliminated 23 PETs which
mapped to multiple loci, and seven PETs that were
unmappable to the genome or mapped to a different
chromosome than initially predicted.
Primer design
For each halftag of each PET, the end internal to the
genomic span of the underlying transcript (not the end
corresponding to the transcript boundary) was lengthened by at least three to five nt (extending toward the
other halftag of the PET) to generate 21 – 23 nt candidate
primers. The primer design criteria were: Tm of 50 to
65°C, GC content of 45 to 60% with no poly-G or poly-C
mononucleotide runs over 3 nt long, a GC clamp at the 3'
end, no palindromes, dimers nor hairpin loops, and Tm

Page 15 of 18
(page number not for citation purposes)

BMC Genomics 2008, 9:155

difference between the forward and reverse primers of less
than 10°C. If a primer was unacceptable, new candidate
primers were obtained by sliding further into the genomic
span of the PET. For halftags supported by exonic overlap
with cDNAs or ESTs on the same strand, we assumed that
the cDNAs/ESTs and the PET represented the same TU,
and incorporated the extent of cDNA/EST exons for
higher-confidence primer design instead of limiting
primer selection to several bases inwards from the PET
boundaries (see Additional file 5 for primer sequences
used in this analysis).
Coding capacity evaluation
The ORF Finder [35] at the NCBI website was used to
identify all potential positive-strand ORFs in the fulllength TU sequences which we obtained from RTPCR
products. The longest positive-strand ORF was selected as
the most probable ORF. BLASTP search was performed to
find its putative conserved domains and homologies to
known protein sequences.
Cell culture
E14 mouse ES cells (ATCC) were cultured, feeder-free, in
gelatin-coated culture dishes containing Dulbecco's modified Eagle's medium (GIBCO), supplemented with 15%
ES cell-qualified fetal bovine serum (GIBCO), 2 mM Lglutamine, 0.1 mM MEM non-essential amino acids,
0.055 mM beta-mercaptoethanol (GIBCO) and 1000
units/ml of LIF (Chemicon). Cells were maintained at
37°C with 5% CO2. For differentiation treatments, cells
were cultured as above but without LIF, and supplemented with one of the differentiation agents. The three
agents were: 0.1 μM retinoic acid (RA), 1% dimethylsulfoxide (DMSO) or 3 mM hexamethylene bisacetamide
(HMBA).
RNA extraction and RTPCR
Total RNA was extracted using TRIzol reagent (Invitrogen)
and purified with the RNAeasy Mini Kit (QIAGEN).
Mouse multi-tissue RNA was purchased from BD Biosciences Clontech (see Additional file 6 for the catalog
numbers). Reverse transcription of 1 μg total RNA was
performed using oligo(dT) priming with the SuperScript
II Kit (Invitrogen). PCR was performed using Platinum
Taq (Invitrogen) with 5% DMSO and the following thermocycler profile: initial denaturation step at 95°C for 10
minutes; 95°C for 30 s followed by primer annealing temperature for 30 s and elongation at 72°C for 1 minute for
40 cycles; final extension step at 72°C for 10 minutes.
PCR products were analyzed on 1.5% agarose gels stained
with ethidium bromide. Whenever the first round of PCR
did not yield any product, a second round of PCR using
either the same primers or nested primers as listed in
Additional file 5 was performed on template generated by
the first PCR reaction because failure to detect a band fol-
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lowing the first reaction could have been due to the low
expression level of the original transcript.
PCR purification, gel extraction, cloning and sequencing
Depending on the gel electrophoresis result, the PCR
product was either purified using the QIAquick PCR Purification Kit (QIAGEN) or, if multiple PCR products were
present on the gel, the band of interest was excised and
purified using QIAquick Gel Extraction Kit (QIAGEN).
The TOPO TA Cloning Kit (Invitrogen) was used to clone
the purified products into TOP10 cells. Plasmid DNA was
isolated using QIAprep Miniprep Kit (QIAGEN) prior to
sequencing using M13 Forward (-20) and Reverse primers.
Quantitative Real-Time PCR
cDNA synthesis of 2 μg total RNA was performed using
High Capacity cDNA Archive Kit (Applied Biosystems)
followed by ten-fold dilution of the product. ABI Prism
7900 Sequence Detection System was used for the QRTPCR analysis. TaqMan Universal PCR Master Mix
(Applied Biosystems) with commercially available prefabricated TaqMan probes (for pluripotency transcription
factors, differentiation markers) and custom-designed
TaqMan probes (for TU11), or SYBR Green Master Mix
(Applied Biosystems) with 5 μM of forward and reverse
primers (for the other transcript sequences) were used as
the reagents in a total volume of 10 μl per sample in a
384-well standard plate. Results were analysed using the
Relative Quantification (ΔΔCt) method using β-Actin as
reference standard. Please see Additional file 7 for the catalog numbers of TaqMan probes used in the QRTPCR
reactions.
Small Interfering RNA (siRNA) Experiments
Custom siRNAs (Dharmacon) were designed against the
novel TUs using siDESIGN Center [36]. For the intergenic
splicing TUs the siRNAs were designed against the unique
exon or against the unique exon-exon boundaries in
TU11, TU52, and TU54 respectively so as not to affect the
expression of their component genes. Dharmacon siCONTROL Non-Targeting siRNAs were used as the negative
control. Mouse E14 ES cells were transfected using DharmaFECT 2 Reagents (Dharmacon) according to the manufacturer's instruction at a density of 1.5 × 105 cells per
well in a 12-well plate. Retransfections were performed at
48-h intervals and the cells were harvested for analysis on
day 3 (for QRTPCR of differentiation markers) and day 5
(for QRTPCR of pluripotency transcription factors).
Please see Additional file 8 for the custom siRNA
sequences used in the experiment.

Abbreviations
ES (cell): embryonic stem (cell). TU: transcriptional unit.
ORF: open reading frame. UTR: untranslated region. EST:
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expressed sequence tag. cDNA: complementary DNA
sequence of a transcript. MPSS: massively parallel signature sequencing. SAGE: serial analysis of gene expression.
RNAi/siRNA: RNA interference/small interfering RNA.
GIS (analysis): Gene Identification Signature analysis.
PET: paired-end ditag. RTPCR: reverse transcriptase –
polymerase chain reaction. QRTPCR: quantitative realtime PCR.

Additional file 7
Catalog numbers of TaqMan probes (Applied Biosystems) used in the
QRTPCR.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S7.pdf]

Additional file 8
Sequences of the custom siRNA (Dharmacon) designed for the TUs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S8.pdf]

Authors' contributions
LL, GK, and LWS designed the project. LL and GK conducted all in-silico sequence analyses. GK and KYW performed the experiments. LWS provided critical guidance.
All authors read and approved the final manuscript.

Additional material
Additional file 1
Detailed PET sequences used in this analysis and the genomic properties
of the 16 novel and putative intergenically spliced TUs selected for experimental validation from the GIS PET-transcriptome dataset.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S1.xls]

Acknowledgements
We would like to thank Linda Lim and other members of GIS Stem Cell &
Developmental Biology group for experimental help and comments. This
work was funded entirely by the Agency for Science, Technology and
Research (A*STAR), Singapore.

References
1.
2.

Additional file 2
Full-length sequences of all splice isoforms of all the 5 TUs studied and the
intergenically spliced transcript found in [11].
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S2.pdf]

Additional file 3
Oct4, Nanog, and Sox2 binding sites in the 100 kb vicinity of the TUs
identified from chromatin immunoprecipitation paired-end diTags
(ChIP-PET) [3] and ChIP-seq [H. H. Ng et al., unpublished].
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S3.pdf]

3.

4.

5.
6.

Additional file 4
Expression levels of the pluripotency markers Oct4, Sox2, Nanog, and
Klf4 upon RA-, DMSO-, and HMBA-induced differentiation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S4.pdf]

7.

Additional file 5

9.

8.

Primer sequences used to characterize the TUs identified in this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S5.pdf]

Additional file 6
Catalog numbers of mouse total RNA (BD Biosciences Clontech) used in
the multi-tissue panel expression analysis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/14712164-9-155-S6.pdf]

10.

11.

Wobus AM, Boheler KR: Embryonic stem cells: prospects for
developmental biology and cell therapy. Physiol Rev 2005,
85:635-678.
Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA,
Jaenisch R, Young RA: Core transcriptional regulatory circuitry
in human embryonic stem cells. Cell 2005, 122:947-956.
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G,
George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD,
Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL,
Ruan Y, Lim B, Ng HH: The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells.
Nat Genet 2006, 38:431-440.
Gan Q, Yoshida T, McDonald OG, Owens GK: Concise review:
epigenetic mechanisms contribute to pluripotency and cell
lineage determination of embryonic stem cells. Stem Cells
2007, 25:2-9.
Richards M, Tan SP, Tan JH, Chan WK, Bongso A: The transcriptome profile of human embryonic stem cells as defined by
SAGE. Stem Cells 2004, 22:51-64.
Wei CL, Miura T, Robson P, Lim SK, Xu XQ, Lee MY, Gupta S, Stanton L, Luo Y, Schmitt J, Thies S, Wang W, Khrebtukova I, Zhou D, Liu
ET, Ruan YJ, Rao M, Lim B: Transcriptome profiling of human
and murine ESCs identifies divergent paths required to
maintain the stem cell state. Stem Cells 2005, 23:166-185.
Brandenberger R, Khrebtukova I, Thies RS, Miura T, Jingli C, Puri R,
Vasicek T, Lebkowski J, Rao M: MPSS profiling of human embryonic stem cells. BMC Dev Biol 2004, 4:10.
Roma G, Cobellis G, Claudiani P, Maione F, Cruz P, Tripoli G, Sardiello M, Peluso I, Stupka S: A novel view of the transcriptome
revealed from gene trapping in mouse embryonic stem cells.
Genome Res 2007, 17:1051-1060.
Sharov AA, Piao Y, Matoba R, Dudekula DB, Qian Y, VanBuren V,
Falco G, Martin PR, Stagg CA, Bassey UC, Wang Y, Carter MG,
Hamatani T, Aiba K, Akutsu H, Sharova L, Tanaka TS, Kimber WL,
Yoshikawa T, Jaradat SA, Pantano S, Nagaraja R, Boheler KR, Taub D,
Hodes RJ, Longo DL, Schlessinger D, Keller J, Klotz E, Kelsoe G,
Umezawa A, Vescovi AL, Rossant J, Kunath T, Hogan BL, Curci A,
D'Urso M, Kelso J, Hide W, Ko MS: Transcriptome analysis of
mouse stem cells and early embryos. PLoS Biol 2003, 1:E74.
Brandenberger R, Wei H, Zhang S, Lei S, Murage J, Fisk GJ, Li Y, Xu
C, Fang R, Guegler K, Rao MS, Mandalam R, Lebkowski J, Stanton LW:
Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation.
Nat Biotechnol 2004, 22:707-716.
Ng P, Wei CL, Sung WK, Chiu KP, Lipovich L, Ang CC, Gupta S, Shahab A, Ridwan A, Wong CH, Liu ET, Ruan Y: Gene identification

Page 17 of 18
(page number not for citation purposes)

BMC Genomics 2008, 9:155

12.

13.
14.

15.

16.

17.
18.

19.

20.

21.

22.

23.
24.
25.

26.

27.

28.

signature (GIS) analysis for transcriptome characterization
and genome annotation. Nat Methods 2005, 2:105-111.
Chen J, Sun M, Lee S, Zhou G, Rowley JD, Wang SM: Identifying
novel transcripts and novel genes in the human genome by
using novel SAGE tags.
Proc Natl Acad Sci USA 2002,
99:12257-12262.
Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler
KW, Velculescu VE: Using the transcriptome to annotate the
genome. Nat Biotechnol 2002, 20:508-512.
Tanaka TS, Kunath T, Kimber WL, Jaradat SA, Stagg CA, Usuda M,
Yokota T, Niwa H, Rossant J, Ko MS: Gene expression profiling
of embryo-derived stem cells reveals candidate genes associated with pluripotency and lineage specificity. Genome Res
2002, 12:1921-1928.
Richards M, Tan SP, Chan WK, Bongso A: Reverse serial analysis
of gene expression (SAGE) characterization of orphan
SAGE tags from human embryonic stem cells identifies the
presence of novel transcripts and antisense transcription of
key pluripotency genes. Stem Cells 2006, 24:1162-1173.
Wang ZX, Kueh JL, Teh CH, Rossbach M, Lim L, Li P, Wong KY,
Lufkin T, Robson P, Stanton LW: Zfp206 is a transcription factor
that controls pluripotency of embryonic stem cells. Stem Cells
2007, 25:2173-2182.
Rhodes DA, de Bono B, Trowsdale J: between SPRY and B30.2
protein domains. Evolution of a component of immune
defence? Immunology 2005, 116:411-417.
Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC: The Clk2 and
Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA
splicing. Exp Cell Res 1998, 241:300-308.
Wu TT, Castle JD: Tyrosine phosphorylation of selected secretory carrier membrane proteins, SCAMP1 and SCAMP3,
and association with the EGF receptor. Mol Biol Cell 1998,
9:1661-1674.
Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura
M, Nishida H, Yap CC, Suzuki M, Kawai J, Suzuki H, Carninci P, Hayashizaki Y, Wells C, Frith M, Ravasi T, Pang KC, Hallinan J, Mattick J,
Hume DA, Lipovich L, Batalov S, Engström PG, Mizuno Y, Faghihi MA,
Sandelin A, Chalk AM, Mottagui-Tabar S, Liang Z, Lenhard B, Wahlestedt C, RIKEN Genome Exploration Research Group; Genome Science Group (Genome Network Project Core Group); FANTOM
Consortium: Antisense transcription in the mammalian transcriptome. Science 2005, 309:1564-1566.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL,
Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson
JA: Induced Pluripotent Stem Cell Lines Derived from
Human Somatic Cells. Science 2007, 318:1917-1920.
Guan K, Nayernia K, Maier LS, Wagner S, Dressel R, Lee JH, Nolte J,
Wolf F, Li M, Engel W, Hasenfuss G: Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 2006,
440:1199-1203.
Koenig M, Monaco AP, Kunkel LM: The complete sequence of
dystrophin predicts a rod-shaped cytoskeletal protein. Cell
1988, 53:219-226.
Akiva P, Toporik A, Edelheit S, Peretz Y, Diber A, Shemesh R, Novik
A, Sorek R: Transcription-mediated gene fusion in the human
genome. Genome Res 2006, 16:30-36.
Parra G, Reymond A, Dabbouseh N, Dermitzakis ET, Castelo R,
Thomson TM, Antonarakis SE, Guigó R: Tandem chimerism as a
means to increase protein complexity in the human
genome. Genome Res 2006, 16:37-44.
Pradet-Balade B, Medema JP, Lopez-Fraga M, Lozano JC, Kolfschoten
GM, Picard A, Martínez-A C, Garcia-Sanz JA, Hahne M: An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell
surface TWEAK-APRIL fusion protein.
EMBO J 2002,
21:5711-5720.
Thomson TM, Lozano JJ, Loukili N, Carrió R, Serras F, Cormand B,
Valeri M, Díaz VM, Abril J, Burset M, Merino J, Macaya A, Corominas
M, Guigó R: Fusion of the human gene for the polyubiquitination coeffector UEV1 with Kua, a newly identified gene.
Genome Res 2000, 10:1743-1756.
Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, Nakashima K,
Gage FH, Rodríguez-Esteban C, Belmonte JC: Maintenance of
embryonic stem cell pluripotency by Nanog-mediated
reversal of mesoderm specification. Nat Clin Pract Cardiovasc
Med 2006, 3(Suppl 1):S114-S122.

http://www.biomedcentral.com/1471-2164/9/155

29.

30.
31.
32.
33.
34.
35.

Suzuki A, Raya A, Kawakami Y, Morita M, Matsui T, Nakashima K,
Gage FH, Rodríguez-Esteban C, Izpisúa Belmonte JC: Nanog binds
to Smad1 and blocks bone morphogenetic protein-induced
differentiation of embryonic stem cells. Proc Natl Acad Sci USA
2006, 103:10294-10299.
Tag-to-genome web browser (T2G)
[http://t2g.bii.astar.edu.sg]. Web site certificate warning: ignore. Username: guest.
Password: guest.
Kent WJ: BLAT – the BLAST-like alignment tool. Genome Res
2002, 12:656-664.
UCSC BLAT Search Site [http://genome.ucsc.edu/cgi-bin/hgBlat]
UCSC In-Silico PCR Site [http://genome.ucsc.edu/cgi-bin/hgPcr]
NCBI ORF Finder Site [http://www.ncbi.nlm.nih.gov/projects/
gorf]
Dharmacon siDESIGN Center [http://www.dharmacon.com/
DesignCenter/DesignCenterPage.aspx]

Publish with Bio Med Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical researc h in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright

BioMedcentral

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Page 18 of 18
(page number not for citation purposes)

